Alligator Bioscience presents the clinical project portfolio at Virtual R&D Day August 27, 2020
Lund, Sweden, August 25, 2020 – Alligator Bioscience (Nasdaq Stockholm: ATORX) will give status updates and details on the recent clinical development plans for the clinical drug candidates mitazalimab, ATOR-1015 and ATOR-1017 on a virtual R&D Day on August 27. “These clinical plans provide an excellent opportunity for Alligator to have two or even three competitive cancer therapeutics in clinical efficacy studies by the end of 2021”, commented Per Norlén, CEO of Alligator Bioscience. Mitazalimab is Alligator’s most advanced immunotherapy candidate intended for the treatment of